challenges of glucose control in ckd

63
Diabetes and Kidney Diabetes and Kidney Dr.Sampathkumar MD,DNB,DM,FRCP MMHRC 1

Upload: drk-sampath-kumar

Post on 07-Jul-2015

182 views

Category:

Health & Medicine


2 download

DESCRIPTION

The incidence of Chronic KidneyDisease[ CKD ] has reached epidemic proportions. Diabetes tops the list of causes of CKD.Both hypo and hyperglycemia can complicate advanced renal disease. The topic is discussed in this presentation

TRANSCRIPT

Page 1: Challenges of glucose control in ckd

Diabetes and KidneyDiabetes and Kidney

Dr.SampathkumarMD,DNB,DM,FRCP

MMHRC

1

Page 2: Challenges of glucose control in ckd

2 sides of the coin 2 sides of the coin

2

Page 3: Challenges of glucose control in ckd

ALL patients with Diabetes and ALL patients with Diabetes and Proteinuria/Renal failure have Proteinuria/Renal failure have

diabetic renal disease .diabetic renal disease .You may be wrong 50% of the

times !

3

Common Pitfall

Page 4: Challenges of glucose control in ckd

Indications for Renal Biopsy Indications for Renal Biopsy

4

Page 5: Challenges of glucose control in ckd

Diabetic N along with Infection Diabetic N along with Infection related GN related GN

Page 6: Challenges of glucose control in ckd

Endocap. Prolif to 100% crescentsEndocap. Prolif to 100% crescents

Page 7: Challenges of glucose control in ckd

Progressive grades of CKDProgressive grades of CKD

7

Page 8: Challenges of glucose control in ckd

Filtration Pressure +15 mm Hg Filtration Pressure +15 mm Hg

8

Page 9: Challenges of glucose control in ckd

Diabetic glomerular diseaseDiabetic glomerular diseaseFlitration Pressure +35Flitration Pressure +35

9

80 mm

Page 10: Challenges of glucose control in ckd

Renal and cv risk increases once Renal and cv risk increases once microalbuminuria crosses 6 mg/gmicroalbuminuria crosses 6 mg/g

Albuminuria Renal risk CV event

0-10 1 1

10-20 2.34 1.9

20-30 12.4 9.8

10

Page 11: Challenges of glucose control in ckd

New classification of albumin New classification of albumin excretionexcretion

11

Page 12: Challenges of glucose control in ckd

12

Page 13: Challenges of glucose control in ckd

13

Page 14: Challenges of glucose control in ckd

Traditional Vs Novel Traditional Vs Novel

14

Page 15: Challenges of glucose control in ckd

Non Proteinuric nephropathyNon Proteinuric nephropathy

15

Page 16: Challenges of glucose control in ckd

16

CKD

Page 17: Challenges of glucose control in ckd

17

This patient develops KWD within 5 years though his Hb A1 c was 6.5 %

Page 18: Challenges of glucose control in ckd

Insulin dynamics in CKDInsulin dynamics in CKD

18

Page 19: Challenges of glucose control in ckd

19

Page 20: Challenges of glucose control in ckd

20

Page 21: Challenges of glucose control in ckd

Insulin half life in CKDInsulin half life in CKD

21

Page 22: Challenges of glucose control in ckd
Page 23: Challenges of glucose control in ckd

23

Page 24: Challenges of glucose control in ckd

24

Page 25: Challenges of glucose control in ckd

Use of OHAs in CKDUse of OHAs in CKD

25

Page 26: Challenges of glucose control in ckd

Metformin Controversy Metformin Controversy in CKD….in CKD….

26

Page 27: Challenges of glucose control in ckd

Pharmacokinetics of MetforminPharmacokinetics of Metformin

27

Page 28: Challenges of glucose control in ckd

MALA- Metformin Associated MALA- Metformin Associated Lactic Acidosis Lactic Acidosis • Decreased Utilisation vs hepatic dysfn

ANAEROBIC GLYCOLYSIS

SHOCK STATES

LIVER DYSFNTYPE B

METFORMIN

•2-10 per 100,000 patients receiving metformin /year•MALA accounts for 0.1-1% total patients admitted to ICU•Mortality is high – 30-50%

Balance

Page 29: Challenges of glucose control in ckd

2 sites where Metformin acts2 sites where Metformin acts

29

Page 30: Challenges of glucose control in ckd

Hypotension rather than Hypotension rather than metformin level which metformin level which determined Lactate accumulationdetermined Lactate accumulation

30

Conclusion from this study

Page 31: Challenges of glucose control in ckd

31

Page 32: Challenges of glucose control in ckd

SFU in CKDSFU in CKD

• Depends on Renal or Hepatic metabolism

• Depends also on whether metabolites have hypoglycemic effects

32

Page 33: Challenges of glucose control in ckd

33

Page 34: Challenges of glucose control in ckd

34

Page 35: Challenges of glucose control in ckd

35

Page 36: Challenges of glucose control in ckd

36

Page 37: Challenges of glucose control in ckd

37

Page 38: Challenges of glucose control in ckd

Drug exposure(AUC) in renal impairment compared to patients Drug exposure(AUC) in renal impairment compared to patients with normal renal functionwith normal renal function

Drug Mild RI Moderate RI Severe RI Hemodialysis

Metformin NA NA NA NA

GlibenclamideM1+M2

NA NA -45% NA

GlimepirideM2

NA -55%+100%

-55%+400%

NA

Repaglinide NA +19% +32% +32%

Pioglitazone NA -17% to -43% 17% to -43% NA

Sitagliptin +61% +126% +277% +350%

Vildagliptin +40% +71% +100% NA

Saxagliptin(Active metabolite)

+16%+67%

+41%+192%

+108%+347%

NANA

Alogliptin +70% +110% +220% +280%

Linagliptin +29% +56% +41% +54%

Exenatide -19% -3% NA +227%

A.J Scheen. Expert Opinion on Drug Metabolism and Toxicology: 2013

Page 39: Challenges of glucose control in ckd

Linagliptin in a recent study lowered albuminuria on top of Linagliptin in a recent study lowered albuminuria on top of standard ACEi/ARB therapy in patients with T2DMstandard ACEi/ARB therapy in patients with T2DM

39

Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy

1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.

**ADA 2012, 953-P

Adjusted mean change in albuminuria(24 weeks)1

24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*

n

95% CI

59

-20%, +23%

168

-42%, -22%

Placebo Linagliptin

-4%

-33%

-29%p < 0.05

Albuminuria:

Early marker for renal damage

Marker for endothelial dysfunction

Cardiovascular risk factor

Lowering of albuminuria is associated with kidney & CV protection

Definitions

Microalbuminuria

UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine

Macroalbuminuria

UACR ≥ 300 mg/g creatinine

-29% in albuminuria vs placeboafter 24 weeks’ treatment**

Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up

to 24 weeks

-29% in albuminuria vs placeboafter 24 weeks’ treatment**

Albuminuria Lowering by Linagliptin is independent of the Improvement in Glucose

Linagliptin significantly lowers albuminuria on top of recommended standard treatment for diabetic nephropathy

1. Inclusion criteria: Stable ACE/ARB background; albuminuria 30−3000 mg/g creatinine; GFR > 30.*Albuminuria-lowering evidence for linagliptin will emerge from MARLINA 1218.89.

**ADA 2012, 953-P

Adjusted mean change in albuminuria(24 weeks)1

24 weeks’ treatmentEffect of linagliptin on albuminuria in humans*

n

95% CI

59

-20%, +23%

168

-42%, -22%

Placebo Linagliptin

-4%

-33%

-29%p < 0.05

Albuminuria:

Early marker for renal damage

Marker for endothelial dysfunction

Cardiovascular risk factor

Lowering of albuminuria is associated with kidney & CV protection

Definitions

Microalbuminuria

UACR ≥ 30 mg/g creatinine < 300 mg/g creatinine

Macroalbuminuria

UACR ≥ 300 mg/g creatinine

-29% in albuminuria vs placeboafter 24 weeks’ treatment**

Proven renal safety with potential for additional kidney benefit– Mean GFR remains unchanged after treatment initiation with linagliptin up

to 24 weeks

-29% in albuminuria vs placeboafter 24 weeks’ treatment**

Possible mechanism: The reno-

protective effect of linagliptin as

studies in preclinical modelInhibition of podocyte damage and

Inhibition of myofibroblast

transformation

Increased GLP-1 receptor

expression

Page 40: Challenges of glucose control in ckd

40

Page 41: Challenges of glucose control in ckd

41

Page 42: Challenges of glucose control in ckd

Extreme Hyperglycemia in CKDExtreme Hyperglycemia in CKD

42

Page 43: Challenges of glucose control in ckd

Case HistoryCase History

• 67 yrs old male in altered sensorium• Type 2 Diabetes, CAD • On OHA for the past 5 y• Fever,Dysuria – 7 d• Pain abdoment -1 d• Altered sensorium – 12 h• On Glimepride, Metformin ,Metoprolol,

Losartan, eplerenone,Asprin,atorvastatin

Page 44: Challenges of glucose control in ckd

Phy ExaminationPhy Examination

• Significant volume depletion• FEBRILE -101,RR 19 /PM• BP -100/70• JVP-Collapsed• S1,S2 FAINT, Lung Bases - clear• Abdomen- Left Lumbar area tender • Catheter draining turbid urine• Drowsy, Neck supple,No FND,Plantar –

Flexor Bil

Page 45: Challenges of glucose control in ckd

LabLab

• Urine – Pus cells +++, Bacteria ++• Hb – 9.8, TC – 18,300. P 84,L14,E2• B.Sugar- 604, B Urea – 87,S.Creat-2.3• Na -147,K – 6.2,Cl – 112, HCO3 – 18.PCO2- 35,pO2 -90• Ketone body – neg• ABG - P H – 7.32

Pyuria Hyperglycemia Azotemia HyperNa,HyperK,Met.Acidosis

Page 46: Challenges of glucose control in ckd

3 major grades of insulin deficits 3 major grades of insulin deficits

Page 47: Challenges of glucose control in ckd

WHY IS HE NOT WHY IS HE NOT KETONEMICKETONEMIC

Page 48: Challenges of glucose control in ckd

Calculated osm

Page 49: Challenges of glucose control in ckd

ECF hyperosmolality produces ICF ECF hyperosmolality produces ICF dehydrationdehydration

RF PREVENTS GLYCOSURIA

Page 50: Challenges of glucose control in ckd

ICF ECF

Na , GK, P

Urea Water

Ethanol

Insulin lack and hyperosmolality drives K outside

Page 51: Challenges of glucose control in ckd

60 kg / 10% Deficit/Na 147 60 kg / 10% Deficit/Na 147

6 / 3L

1 L/I hr

0.45%Sal.

H2O /po

Page 52: Challenges of glucose control in ckd

Insulin therapy Insulin therapy

Page 53: Challenges of glucose control in ckd

53

Page 54: Challenges of glucose control in ckd
Page 55: Challenges of glucose control in ckd

Hemodialysis for severe Hemodialysis for severe hyperglycemia in CKDhyperglycemia in CKD

55

Extreme hyperglycemia with ketoacidosis and hyperkalemia in a patient on chronic hemodialysis.Hemodial Int. 2008 Oct ;12 Suppl 2:S43-7.

Page 56: Challenges of glucose control in ckd

56

Page 57: Challenges of glucose control in ckd

CAPD patientCAPD patient

• Dialysate contains • Glucose in high• Concentration

• Hyperglycemia severe and common

57

Page 58: Challenges of glucose control in ckd

Icodextrin use in diabetic patientIcodextrin use in diabetic patient• Icodextrin is

Polymer of Glucose• False high reading of

Blood Glucose if • GDH/PQQ strips

are used • Risk of iatrogenic

hypoglycemia due to misdiagnosis and over reaction

58

Page 59: Challenges of glucose control in ckd

Renal Transplantation.Renal Transplantation.

59

Page 60: Challenges of glucose control in ckd

Post transplant DiabetesPost transplant Diabetes

• Tacrolimus• Cyclosporine• Steroids• CMV• HCV • Metabolic syndrome

60

Page 61: Challenges of glucose control in ckd

45 yrs female , Renal TX in 45 yrs female , Renal TX in MMHRC at 1999.Presents with MMHRC at 1999.Presents with proteinuria , edemaproteinuria , edema

61

Page 62: Challenges of glucose control in ckd

Arteriolar hyalinosisArteriolar hyalinosis

62

Page 63: Challenges of glucose control in ckd

63

Hypoglycemia Vs Hyperglycemia in Hypoglycemia Vs Hyperglycemia in CKD- Tight rope walk!CKD- Tight rope walk!

If he falls your reputation also falls !!